Spots Global Cancer Trial Database for pathologic stage iii gastroesophageal junction adenocarcinoma ajcc v8

Every month we try and update this database with for pathologic stage iii gastroesophageal junction adenocarcinoma ajcc v8 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma	NCT04097028	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag...	Trifluridine an... Oxaliplatin	18 Years -	Roswell Park Cancer Institute
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial	NCT04704661	Advanced Breast... Advanced Colon ... Advanced Colore... Advanced Endome... Advanced Gastri... Advanced Gastro... Advanced Malign... Advanced Saliva... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... HER2-Positive B... Malignant Hepat... Metastatic Brea... Metastatic Gast... Metastatic Mali... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Colon... Stage III Color... Stage III Major... Stage III Uteri... Stage IIIA Colo... Stage IIIA Colo... Stage IIIA Uter... Stage IIIB Colo... Stage IIIB Colo... Stage IIIB Uter... Stage IIIC Colo... Stage IIIC Colo... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Colon ... Stage IV Colore... Stage IV Major ... Stage IV Uterin... Stage IVA Colon... Stage IVA Color... Stage IVA Major... Stage IVA Uteri... Stage IVB Colon... Stage IVB Color... Stage IVB Major... Stage IVB Uteri... Stage IVC Colon... Stage IVC Color... Stage IVC Major... Unresectable Co... Unresectable Ga... Unresectable Ma...	Ceralasertib Trastuzumab Der...	18 Years -	National Cancer Institute (NCI)
Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma	NCT04097028	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag...	Trifluridine an... Oxaliplatin	18 Years -	Roswell Park Cancer Institute
Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study	NCT03707574	Advanced Malign... Advanced Melano... Advanced Renal ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Color... Stage III Lung ... Stage III Ovari... Stage III Prost... Stage IIIA Colo... Stage IIIA Lung... Stage IIIA Ovar... Stage IIIA Pros... Stage IIIA1 Ova... Stage IIIA2 Ova... Stage IIIB Colo... Stage IIIB Lung... Stage IIIB Ovar... Stage IIIB Pros... Stage IIIC Colo... Stage IIIC Lung... Stage IIIC Ovar... Stage IIIC Pros... Stage IV Colore... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IVA Color... Stage IVA Lung ... Stage IVA Ovari... Stage IVA Prost... Stage IVB Color... Stage IVB Lung ... Stage IVB Ovari... Stage IVB Prost... Stage IVC Color...	Biospecimen Col...	18 Years -	National Cancer Institute (NCI)
Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma	NCT03784326	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag...	Atezolizumab Conventional Su... Fluorouracil Oxaliplatin Tiragolumab	18 Years -	M.D. Anderson Cancer Center
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma	NCT05041153	Advanced Gastri... Advanced Gastro... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Gast... Metastatic Gast... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Unresectable Ga... Unresectable Ga...	Lenvatinib Pembrolizumab	18 Years -	M.D. Anderson Cancer Center
Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery	NCT04391049	Advanced Esopha... Advanced Gastro... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Unresectable Ga... Squamous Cell C... Squamous Cell C...	Carboplatin Paclitaxel Radiation Thera... Telomerase-spec...	18 Years -	NRG Oncology
Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer	NCT04522336	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Localized Gastr... Locally Advance... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Unresectable Ga...	Docetaxel Fluorouracil Oxaliplatin Pembrolizumab Radiation Thera...	18 Years -	M.D. Anderson Cancer Center
Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery	NCT04391049	Advanced Esopha... Advanced Gastro... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Unresectable Ga... Squamous Cell C... Squamous Cell C...	Carboplatin Paclitaxel Radiation Thera... Telomerase-spec...	18 Years -	NRG Oncology
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers	NCT04460937	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Distal Esophagu... Gastric Cardia ... Metastatic Esop... Metastatic Esop... Metastatic Gast... Metastatic Mali... Metastatic Mali... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Unresectable Es... Unresectable Es... Unresectable Es... Unresectable Ga...	Adavosertib Radiation Thera...	18 Years -	National Cancer Institute (NCI)
Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer	NCT04522336	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Localized Gastr... Locally Advance... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Unresectable Ga...	Docetaxel Fluorouracil Oxaliplatin Pembrolizumab Radiation Thera...	18 Years -	M.D. Anderson Cancer Center
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer	NCT03801876	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Thoracic Esopha...	Carboplatin Esophagectomy Intensity-Modul... Paclitaxel Proton Beam Rad... Quality-of-Life... Questionnaire A... FOLFOX regimen CAPOX regimen Docetaxel 5FU	18 Years -	NRG Oncology
Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers	NCT05296005	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Gastric Adenoca... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag...	Capecitabine Docetaxel Fluorouracil Leucovorin Oxaliplatin Radiation Thera... Surgical Proced...	18 Years -	Ohio State University Comprehensive Cancer Center
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer	NCT04660760	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant...	Paclitaxel Quality-of-Life... Ramucirumab Trifluridine an...	18 Years -	Academic and Community Cancer Research United

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: